ACRV · Acrivon Therapeutics Inc
United States · RS rating 42 · As of 2026-11-03
| Price | 1.67 USD |
|---|---|
| 1-day change | +3.7% |
| RS rating (overall / 1M / 3M / 12M) | 42 / 26 / 71 / 39 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 15 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +12.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +44.5% |
| Market cap (USD) | $73.2M |